Avandia Tagged Articles
Study shows high-fat, low-carb diets are better for type 2 diabetics
High-fat, low-carb diets help control blood sugar levels better than low-fat diets and are ultimately better for type 2 diabetics, according to a new study published in the journal Diabetologia. The findings buck the long-held recommendation that people with diabetes
Diabetics urged to avoid Actos due to cancer risk
People with type 2 diabetes should use the drug Actos (pioglitazone) only if all other options have failed, and people with pre-diabetes should never use it, says Consumer Reports, the well-known consumer watchdog organization.
Kids with type 2 diabetes have limited treatment options
The rising number of kids being diagnosed with type 2 diabetes has created new challenges on how to manage the “adult-onset” disease in young people, according to concerns raised at a recent meeting of pediatricians in Boston.
Public Citizen petitions FDA to ban diabetes drug Victoza due to thyroid cancer risk
Public watchdog group Public Citizen is petitioning the U.S. Food and Drug Administration (FDA) to pull the type 2 diabetes drug Victoza off the market because it puts patients at higher risk for thyroid cancer, pancreatitis, serious allergic reactions, and
FDA wants more safety data before it will approve new type 2 diabetes drugs
Takeda Pharmaceutical Co. will have to produce more evidence on the safety of two new type 2 diabetes medications, delaying even more what has been a long road to Food and Drug Administration (FDA) approval. Takeda is seeking United States
Actos linked to serious psychiatric impairments, medical reviewer alleges
The diabetes drug Actos is linked to higher rates of suicide, schizophrenia, epilepsy, and grand mal seizures compared to other drugs in the same class, such as Avandia, says Dr. Helen Ge, a former medical reviewer in Takeda Pharmaceuticals’ pharmacovigilance
Health Canada puts bladder cancer warning on diabetes drug Actos
Health Canada is warning citizens that the type 2 diabetes drug Actos (pioglitazone) may cause bladder cancer. The announcement was made following a months-long safety assessment by the Canadian drug regulator. Health Canada began the assessment last June, two days
Canada regulators issue Actos bladder cancer warning
New studies reveal that patients taking the diabetes drug Actos (pioglitazone) face a potentially elevated risk of bladder cancer, warned Canada’s healthcare regulatory agency Health Canada. The announcement, issued jointly with the drug’s manufacturer, Takeda Canada Inc., comes after an
New therapy could one day provide better treatment options for diabetics
A novel new therapy to treat type 2 diabetes that lowers blood sugar, decreases insulin resistance, lowers cholesterol and helps keep fatty deposits from settling in the liver is in the works at Columbia University Medical Center, and researchers hope
